327 related articles for article (PubMed ID: 33199206)
1. 5-Aminolevulinate dehydratase porphyria: Update on hepatic 5-aminolevulinic acid synthase induction and long-term response to hemin.
Lahiji AP; Anderson KE; Chan A; Simon A; Desnick RJ; Ramanujam VMS
Mol Genet Metab; 2020 Dec; 131(4):418-423. PubMed ID: 33199206
[TBL] [Abstract][Full Text] [Related]
2. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
Wang B; Bonkovsky HL; Lim JK; Balwani M
Gastroenterology; 2023 Mar; 164(3):484-491. PubMed ID: 36642627
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs).
Bonkovsky HL; Dixon N; Rudnick S
Mol Genet Metab; 2019 Nov; 128(3):213-218. PubMed ID: 30987916
[TBL] [Abstract][Full Text] [Related]
4. Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.
Yasuda M; Erwin AL; Liu LU; Balwani M; Chen B; Kadirvel S; Gan L; Fiel MI; Gordon RE; Yu C; Clavero S; Arvelakis A; Naik H; Martin LD; Phillips JD; Anderson KE; Sadagoparamanujam VM; Florman SS; Desnick RJ
Mol Med; 2015 Jun; 21(1):487-95. PubMed ID: 26062020
[TBL] [Abstract][Full Text] [Related]
5. Givosiran: A Review in Acute Hepatic Porphyria.
Syed YY
Drugs; 2021 May; 81(7):841-848. PubMed ID: 33871817
[TBL] [Abstract][Full Text] [Related]
6. 5-Aminolevulinic acid dehydratase deficiency porphyria: a twenty-year clinical and biochemical follow-up.
Gross U; Sassa S; Jacob K; Deybach JC; Nordmann Y; Frank M; Doss MO
Clin Chem; 1998 Sep; 44(9):1892-6. PubMed ID: 9732973
[TBL] [Abstract][Full Text] [Related]
7. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
Sardh E; Harper P
J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria.
Graff E; Anderson KE; Levy C
Front Genet; 2022; 13():867856. PubMed ID: 35991568
[No Abstract] [Full Text] [Related]
9. Recent advances on porphyria genetics: Inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes.
Yasuda M; Chen B; Desnick RJ
Mol Genet Metab; 2019 Nov; 128(3):320-331. PubMed ID: 30594473
[TBL] [Abstract][Full Text] [Related]
10. Givosiran for the treatment of acute hepatic porphyria.
Ricci A; Ventura P
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):383-393. PubMed ID: 35531651
[TBL] [Abstract][Full Text] [Related]
11. RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice.
Yasuda M; Gan L; Chen B; Kadirvel S; Yu C; Phillips JD; New MI; Liebow A; Fitzgerald K; Querbes W; Desnick RJ
Proc Natl Acad Sci U S A; 2014 May; 111(21):7777-82. PubMed ID: 24821812
[TBL] [Abstract][Full Text] [Related]
12. Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.
Wang B; Ventura P; Takase KI; Thapar M; Cassiman D; Kubisch I; Liu S; Sweetser MT; Balwani M
Orphanet J Rare Dis; 2022 Aug; 17(1):327. PubMed ID: 36028858
[TBL] [Abstract][Full Text] [Related]
13. [delta-Aminolevulinate dehydratase deficiency].
Fujita H; Ishida N; Akagi R
Nihon Rinsho; 1995 Jun; 53(6):1408-17. PubMed ID: 7616655
[TBL] [Abstract][Full Text] [Related]
14. Hypothesis: Metabolic targeting of 5-aminolevulinate synthase by tryptophan and inhibitors of heme utilisation by tryptophan 2,3-dioxygenase as potential therapies of acute hepatic porphyrias.
Badawy AA
Med Hypotheses; 2019 Oct; 131():109314. PubMed ID: 31443750
[TBL] [Abstract][Full Text] [Related]
15. Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver.
Schmitt C; Lenglet H; Yu A; Delaby C; Benecke A; Lefebvre T; Letteron P; Paradis V; Wahlin S; Sandberg S; Harper P; Sardh E; Sandvik AK; Hov JR; Aarsand AK; Chiche L; Bazille C; Scoazec JY; To-Figueras J; Carrascal M; Abian J; Mirmiran A; Karim Z; Deybach JC; Puy H; Peoc'h K; Manceau H; Gouya L
J Intern Med; 2018 Jul; 284(1):78-91. PubMed ID: 29498764
[TBL] [Abstract][Full Text] [Related]
16. The third case of Doss porphyria (delta-amino-levulinic acid dehydratase deficiency) in Germany.
Doss MO; Stauch T; Gross U; Renz M; Akagi R; Doss-Frank M; Seelig HP; Sassa S
J Inherit Metab Dis; 2004; 27(4):529-36. PubMed ID: 15303011
[TBL] [Abstract][Full Text] [Related]
17. ALAD Inhibition by Porphobilinogen Rationalizes the Accumulation of δ-Aminolevulinate in Acute Porphyrias.
San Juan I; Pereira-Ortuzar T; Cendoya X; Laín A; To-Figueras J; Mateos B; Planes FJ; Bernardo-Seisdedos G; Mato JM; Millet O
Biochemistry; 2022 Nov; 61(21):2409-2416. PubMed ID: 36241173
[TBL] [Abstract][Full Text] [Related]
18. Novel molecular defects of the delta-aminolevulinate dehydratase gene in a patient with inherited acute hepatic porphyria.
Akagi R; Shimizu R; Furuyama K; Doss MO; Sassa S
Hepatology; 2000 Mar; 31(3):704-8. PubMed ID: 10706561
[TBL] [Abstract][Full Text] [Related]
19. ALAD porphyria.
Sassa S
Semin Liver Dis; 1998; 18(1):95-101. PubMed ID: 9516683
[TBL] [Abstract][Full Text] [Related]
20. Givosiran to treat acute porphyria.
Honor A; Rudnick SR; Bonkovsky HL
Drugs Today (Barc); 2021 Jan; 57(1):47-59. PubMed ID: 33594389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
